Home / Resource Library / A phase II, multicenter, single-arm study of parsaclisib, a PI3K inhibitor, in relapsed or refractory follicular lymphoma in China: Updated data from the study
A phase II, multicenter, single-arm study of parsaclisib, a PI3K inhibitor, in relapsed or refractory follicular lymphoma in China: Updated data from the study